Abeona Therapeutics (ABEO) Stock Statistics & Valuation Metrics

Abeona Therapeutics has a market cap or net worth of $241.32M. The enterprise value is $225.61M.

Market Cap

$241.32M

Enterprise Value

$225.61M

Abeona Therapeutics has 57,184,017 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

57,184,017

Owned by Insiders

6.19%

Owned by Institutions

21.70%

Abeona Therapeutics’s return on equity (ROE) is 0.45 and return on invested capital (ROIC) is -43.98%.

Return on Equity (ROE)

0.45

Return on Assets (ROA)

0.32

Return on Invested Capital (ROIC)

-43.98%

Return on Capital Employed (ROCE)

-0.47

Revenue Per Employee

25.75K

Profits Per Employee

314.97K

Employee Count

226

Asset Turnover

0.03

Inventory Turnover

0.28

The current PE Ratio of Abeona Therapeutics is -3.44. Abeona Therapeutics’s PEG ratio is 0.02.

PE Ratio

-3.44

PS Ratio

8.76

PB Ratio

1.74

Price to FCF

-2.74

Price to Operating Cash Flow

-2.92

PEG Ratio

0.02

In the last 12 months, Abeona Therapeutics had revenue of 5.82M and earned 71.18M in profits. Earnings per share was 1.34.

Revenue

5.82M

Gross Profit

4.29M

Operating Income

-89.45M

Pretax Income

71.28M

Net Income

71.18M

EBITDA

78.59M

Earnings Per Share (EPS)

1.34

In the last 12 months, operating cash flow was -76.44M and capital expenditures -5.09M, giving a free cash flow of -81.53M billion.

Operating Cash Flow

-76.44M

Free Cash Flow

-81.53M

Free Cash Flow per Share

-1.43

Abeona Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-36.46%

Earnings Yield

-28.19%

Beta

1.58

52-Week Price Change

-10.32%

50-Day Moving Average

5.17

200-Day Moving Average

5.49

Relative Strength Index (RSI)

27.03

Average Volume (3m)

1.36M

Abeona Therapeutics upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 13, 2026

Next Earnings Date

Nov 16, 2026

Ex-Dividend Date

―

Abeona Therapeutics as a current ratio of 6.93, with Debt / Equity ratio of 15.68%

Current Ratio

6.93

Quick Ratio

6.74

Debt to Market Cap

0.07

Net Debt to EBITDA

-0.68

Interest Coverage Ratio

-23.92

In the past 12 months, Abeona Therapeutics has paid 100.00K in taxes.

Income Tax

100.00K

Effective Tax Rate

0.00

Abeona Therapeutics EV to EBITDA ratio is -2.63, with an EV/FCF ratio of -2.30.

EV to Sales

7.34

EV to EBITDA

-2.63

EV to Free Cash Flow

-2.30

EV to Operating Cash Flow

-2.45

Abeona Therapeutics has $146.83M in cash and marketable securities with $19.87M in debt, giving a net cash position of $126.95M billion.

Cash & Marketable Securities

$146.83M

Total Debt

$19.87M

Net Cash

$126.95M

Net Cash Per Share

$2.22

Tangible Book Value Per Share

$2.24

Gross margin is 56.63%, with operating margin of -327.64%, and net profit margin of -246.42%.

Gross Margin

56.63%

Operating Margin

-327.64%

Pretax Margin

-306.81%

Net Profit Margin

-246.42%

EBITDA Margin

-279.40%

EBIT Margin

-293.83%

The average price target for Abeona Therapeutics is $22.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$22.00

Price Target Upside

462.66% Upside

Analyst Consensus

Strong Buy

Analyst Count

4

Revenue Growth Forecast

6280.00%

EPS Growth Forecast

-212.54%

Smart Score

5

AI Score

47